Please try another search
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.
Name | Age | Since | Title |
---|---|---|---|
Gwill York | 66 | 2021 | Independent Director |
Thomas R. Insel | 71 | - | Scientific Advisor |
Po Yu Chen | 43 | 2022 | Non-Employee Independent Director |
Madhukar H. Trivedi | - | - | Scientific Advisor |
Fei-Fei Li | 48 | - | Scientific Advisor |
Husseini K. Manji | 65 | 2024 | Non-Employee Independent Director |
Christopher Nixon Cox | 44 | 2022 | Lead Independent Director |
Alan F. Schatzberg | 79 | - | Scientific Advisor |
Andrew C. Dreyfus | 65 | 2023 | Independent Director |
Amit Etkin | 47 | 2019 | Founder, Chairman of the Board, CEO & President |
Quentin Huys | - | - | Scientific Advisor |
Mahalakshmi Radhakrishnan | 54 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review